Organelles in cells were originally often independent cells, which were incorporated by host cells and lost their ...

In the search for solutions to diseases like cancer, scientists are pursuing a new frontier in biology—the spatial and ...

Researchers at the University of Turku, Finland, investigated how to use bio-based materials to produce effective UV ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

An openly available generative AI tool can interpret millions of cells in human tissues in hours, revealing new insights and allowing researchers and clinicians to ask questions about conditions such ...

AstraZeneca’s EsoBiotec acquisition is the latest in a series of deals struck by the pharma giant to secure a place in the next wave of cell therapies for cancer and immune-mediated diseases.

AstraZeneca (AZ) has announced that it will be expanding its cell therapy capabilities by acquiring EsoBiotec for up to $1bn. The deal will give AZ access to EsoBiotec’s Engineered NanoBody Lentiviral ...

This article explores the transformative role of artificial intelligence (AI) in deciphering the complex molecular and genetic codes that govern biological and chemical processes. From molecular ...

British-Swedish multinational pharmaceutical and biotechnology company AstraZenica on Monday announced the acquisition of ...

AstraZeneca to buy in vivo cell therapy company, EsoBiotec for US$ 1billion: Cambridge, UK Tuesday, March 18, 2025, 10:00 Hrs [IST] AstraZeneca, a global, science-led biopharmaceu ...

The deals are expected to shorten manufacturing timelines for cell therapies and reduce administration times for oncology ...

EsoBiotec develops therapies that engineer immune cells within the body, eliminating the need for patients to go through lymphodepletion and reinfusion.